drugset / Trial / NCT00647920

Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00647920

Phase 3 Completed 47 enrolled Abbott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Study of the Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated with Methotrexate

Timeline

Start
2003-07
Primary completion
2005-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications